The Relationship Between XinKang-I and Chronic Heart Failure

Traditional Chinese Medicine Clinical Trial

Official title:

The Relationship Between XinKang-I and Chronic Heart Failure: Protocol for a Randomized Controlled Study.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05847959
• Other study ID #: DongguanHTCM
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 1, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: April 2023
• Source: Dongguan Hospital of Traditional Chinese Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: Heart failure is the severe and terminal stage of various heart diseases, which is characterized by high morbidity, mortality and readmission. There are few studies on the relationship between XinKang-I(XK-I) and chronic heart failure.

Objective: To explore the relationship between XK-I and chronic heart failure. Methods/design: The trial is a single-center, single-blind, randomized study (1:1). It will recruit 110 patients with chronic heart failure who syndrome of qi deficiency yang deficiency and blood stasis. The intervention group will receive not only Western medicine, but also XK-I. The primary end points will be the changes in oxygen consumption volume of anaerobic threshold (VO2AT), maximum oxygen volume uptake (VO2max), and 6-minute walking distance after 8 weeks of treatment. Both groups will receive 8 weeks of treatment.

Ethics and dissemination: Ethical approval was granted by Ethics Committee of Dongguan TCM Hospital. Results will be disseminated via peer-reviewed publications and presentations at international conferences.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 110
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. History of CHF or clinical findings of CHF for more than 3 months. CHF was diagnosed in accordance with the European Society of Cardiology's 2021 Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.

2. Patients ranged in age from 18 to 85.

3. Cardiac function was graded at grade II-IV (New York Heart Association functional class).

4. Patients who had not used traditional Chinese medicine for treating heart failure within 1 week before enrollment;

5. Written informed consent will be obtained.

Exclusion Criteria:

1. acute cardiac insufficiency, acute myocarditis, severe valvular heart disease, malignant arrhythmia, obstructive cardiomyopathy, pericardial tamponade, constrictive pericarditis or acute coronary syndrome

2. severe lung, liver or kidney dysfunction

3. nervous and hematopoietic system

4. malignant tumors

5. hemodynamic nstability

6. pulmonary embolism

7. severe infection

8. pregnant or lactating

9. refusal to provide written informed consent for this study

Related Conditions & MeSH terms

• Heart Failure
• Traditional Chinese Medicine

Intervention

Drug:
• Traditional Chinese medicine prescription:XinKang-I
XK-I will be used in intervention group (20 grams of radix astragalus, 20 grams of radix codonopsis, 10 grams of stir-fried semen lepidii, 8 grams of sweet apricot kernel, 10 grams of cassia twig, 15 grams of poria cocos, 10 grams of atractylodes, 5 grams of honey-roasted licorice, 15 grams of radix et rhizoma salviae miltiorrhizae, 10 grams of chuanxiong rhizoma, 5 grams of tangerine peel).Patients will take XK-I once a day, divided into morning and evening administration. The treatment lasted for 8 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Dongguan Hospital of Traditional Chinese Medicine

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The changes in 6-minute walking distance(distance, meter).	Cardiac function	8 weeks
Primary	oxygen consumption volume of anaerobic threshold (VO2AT, ml)	Cardiac function	8 weeks
Primary	maximum oxygen volume uptake (VO2max, ml/min) in cardiopulmonary function test	Cardiac function	8 weeks